---
title: "PACAP-38"
canonical_url: https://peptidelibrary.app/library/pacap-38
description: "38-aa neuropeptide that activates PAC1/VPAC receptors. Research tool in migraine, neuroprotection, and metabolic models. Not FDA-approved as a drug."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# PACAP-38

PACAP-38 (also called Pituitary adenylate cyclase-activating polypeptide-38) is an endogenous neuropeptide in the VPAC/PAC1 agonist class. Pituitary adenylate cyclase-activating polypeptide is a 38-amino-acid neuropeptide closely related to vasoactive intestinal peptide, sharing roughly two-thirds sequence identity. It binds the PAC1 receptor with high selectivity and also engages VPAC1 and VPAC2; all are Gs-coupled, so activation raises cyclic AMP in neurons and endocrine cells.

38-aa neuropeptide that activates PAC1/VPAC receptors. Research tool in migraine, neuroprotection, and metabolic models. Not FDA-approved as a drug.

Also known as: Pituitary adenylate cyclase-activating polypeptide-38.

Categories: Fat Loss, Cognitive, GLP-1/Metabolic, Experimental.

## Classification

- Type: Endogenous neuropeptide / research
- Mechanism class: VPAC/PAC1 agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Pituitary adenylate cyclase-activating polypeptide is a 38-amino-acid neuropeptide closely related to vasoactive intestinal peptide, sharing roughly two-thirds sequence identity. It binds the PAC1 receptor with high selectivity and also engages VPAC1 and VPAC2; all are Gs-coupled, so activation raises cyclic AMP in neurons and endocrine cells. Reported roles include neurotrophic and neuroprotective signalling, regulation of catecholamine release from the adrenal medulla, and circadian modulation. It has a distinctive place in human research because intravenous infusion reliably triggers migraine-like headache in susceptible people, which established the PACAP pathway as a migraine target and led to therapeutic antibodies against it.

Targets: PAC1, VPAC1, VPAC2.

Origin: Endogenous neuropeptide; synthetic research material.

## Properties

- Molecular formula: C203H331N63O53S
- Molecular weight: ≈4534 g/mol
- CAS number: 137061-48-4
- Half-life: Very short; rapidly degraded by peptidases
- Studied routes: Intravenous

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 3
- Preclinical sources: 0
- Latest source: 2025

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept. 2007. 2007. Controlled human trial. Population: Healthy young volunteers (n=12). No major direct effect on regional cerebral blood flow; heart rate rose by about 62%, which the authors called a dose-limiting factor [Source](https://pubmed.ncbi.nlm.nih.gov/17320198/)
2. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009. 2009. Controlled human trial. Population: 12 healthy people and 12 people with migraine without aura. Headache in all healthy people and 11 of 12 with migraine; 7 of 12 with migraine had migraine-like attacks after PACAP-38 and none after placebo, mostly hours later [Source](https://pubmed.ncbi.nlm.nih.gov/19052139/)
3. PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial. J Headache Pain. 2025. 2025. Controlled human trial. Population: Adults with migraine without aura (n=38). Migraine attacks in 10 of 19 after eptinezumab and 12 of 19 after placebo, no significant difference; no serious adverse events [Source](https://pubmed.ncbi.nlm.nih.gov/40229719/)

## Safety

Side effects: Flushing; Headache / migraine provocation.

Risks: Not a therapeutic as sold in research vials.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

PACAP-38 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is PACAP-38?

38-aa neuropeptide that activates PAC1/VPAC receptors. Research tool in migraine, neuroprotection, and metabolic models. Not FDA-approved as a drug.

### How does PACAP-38 work?

Pituitary adenylate cyclase-activating polypeptide is a 38-amino-acid neuropeptide closely related to vasoactive intestinal peptide, sharing roughly two-thirds sequence identity. It binds the PAC1 receptor with high selectivity and also engages VPAC1 and VPAC2; all are Gs-coupled, so activation raises cyclic AMP in neurons and endocrine cells.

### Is PACAP-38 FDA approved?

No. PACAP-38 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of PACAP-38?

Reported half-life for PACAP-38 is Very short; rapidly degraded by peptidases. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What peptides are similar to PACAP-38?

Compounds most often compared with PACAP-38 include 5-Amino-1MQ, Adamax, Adipotide and AICAR. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial — J Headache Pain, 2025](https://pubmed.ncbi.nlm.nih.gov/40229719/)
- [Part I: Pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine — Cephalalgia, 2017](https://pubmed.ncbi.nlm.nih.gov/26994299/)
- [PACAP-38 is increased in the tear fluid of patients with migraine — J Neurol Neurosurg Psychiatry, 2026](https://pubmed.ncbi.nlm.nih.gov/41850768/)
- [Activation and sensitization of meningeal nociceptors by PACAP-38: implications for migraine headache — Brain, 2026](https://pubmed.ncbi.nlm.nih.gov/40795030/)
- [Pituitary adenylate cyclase-activating polypeptide (PACAP-38) plays an inhibitory role against inflammation induced by chemical damage to zebrafish hair cells — PLoS One, 2018](https://pubmed.ncbi.nlm.nih.gov/29856797/)
